Lipitor II
Executive Summary
After hosting delegations of licensing hopefuls for its phase III Cox-2 inhibitor, Searle chose Pfizer Inc., the industry's most aggressive and probably most successful co-promoter. Searle's next likely co-promotion announcements will concern its phase IIb/IIIa platelet inhibitors.